Diabetes drugs that also promote weight loss such as Novo Nordisk’s Ozempic, becoming a darling of celebrities and investors, are being studied to tackle some of the most difficult-to-treat brain disorders, including Alzheimer’s disease.
By Julie Steenhuysen CHICAGO (Reuters) - People at high risk of severe disease who have yet to get a second COVID-19 booster should not wait for next-.
By Julie Steenhuysen CHICAGO (Reuters) - People at high risk of severe disease who have yet to get a second COVID-19 booster should not wait for next-.